Clinical Trial

Epcoritamab-CAR T Cells for Large B-cell Lymphomas

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat that lymphoma.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-06-12; most recent amendment 2026-05-22.
Status change: Not Yet Recruiting → Recruiting 2024-10-09
Trial Details
NCT Number NCT06458439
Lead Sponsor Abramson Cancer Center at Penn Medicine
Collaborators: Genmab
Conditions Lymphoma, Non-Hodgkin, Relapsed Diffuse Large B Cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, Transformed Indolent Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Enrollment 31 participants
Start Date 2024-09-24
Primary Completion 2027-10 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-27